Belly Fat May Matter More Than BMI for Heart Failure Risk

Belly Fat May Matter More Than BMI for Heart Failure Risk

For decades, body mass index has been the quick shorthand for whether someone’s weight may be affecting their health.

It is easy to calculate, easy to compare across populations, and widely used in clinical practice. But when it comes to heart failure and broader cardiovascular risk, the science is becoming increasingly clear on one point: BMI may not be asking the most important question.

That question is not simply how much body fat a person has. It is where that fat is stored.

A growing body of evidence suggests that abdominal fat — particularly visceral fat, which sits deep around internal organs — may be more informative than BMI alone when it comes to heart failure risk and inflammatory burden. That matters because BMI cannot distinguish between types of fat, fat location, or how metabolically harmful that fat may be.

In other words, two people can have the same BMI and very different levels of cardiovascular danger.

Why BMI only tells part of the story

BMI was never designed to be a full metabolic assessment tool. It is a broad population-level measure of weight relative to height. That gives it real value in screening and public health surveillance, but also obvious limitations.

It cannot tell muscle from fat. It cannot show whether fat is stored mostly under the skin or deeper in the abdomen. And it cannot capture the biological behaviour of that fat.

This is why clinicians have long known that BMI sometimes fails to match what they see in practice. Some people with a relatively modest BMI carry clear metabolic risk, while others with a similar BMI do not. The missing piece is often fat distribution.

The literature supplied here supports that concern. It points to BMI as an incomplete marker of cardiovascular risk because it cannot distinguish fat quality or location. That may be especially important in heart failure, where systemic inflammation, impaired fitness and adverse tissue remodelling all play a role.

Why abdominal fat is different

Not all body fat acts in the same way.

Subcutaneous fat, stored just beneath the skin, is different from visceral fat, which accumulates around the abdominal organs. Visceral fat is more metabolically active and more closely tied to insulin resistance, chronic low-grade inflammation, and the kind of physiological stress that pushes the cardiovascular system in the wrong direction.

One of the most relevant reviews in the supplied literature, focused on regional adiposity and heart failure with preserved ejection fraction, reports that waist circumference, waist-to-hip ratio, epicardial fat and visceral fat are more strongly linked to heart failure risk profiles than subcutaneous fat.

That review also connects regional adiposity to local and systemic inflammation, poorer cardiorespiratory fitness and adverse cardiac mechanics.

This is a crucial shift in emphasis. The concern is not simply body size. It is the biological consequences of where fat is deposited and how that deposit interacts with the heart, vessels and metabolism.

The inflammation link

One of the main reasons abdominal fat may matter more than BMI is that it appears to be more closely linked to inflammation.

The supplied cardiovascular epidemiology review argues that visceral obesity is more closely tied than BMI to inflammation, insulin resistance and harmful cardiovascular outcomes. That helps explain why a person may not look dramatically high-risk through a BMI lens, yet still carry a much more adverse cardiometabolic profile.

Inflammation matters in heart failure because it is not simply a by-product of disease. It may be part of the environment that helps drive it.

Additional data included in the evidence set show that inflammatory markers such as C-reactive protein are strongly associated with frailty and more adverse profiles in heart failure patients. Although that particular paper is more focused on frailty within established heart failure than on incident disease risk, it strengthens the broader case that inflammation is central to the condition and that adiposity patterns associated with inflammation deserve closer attention.

The heart appears to care where fat is stored

This may be the most useful take-home message from the overall evidence.

The heart does not seem to respond simply to total body weight. It responds to the metabolic and inflammatory environment in which it is operating. And abdominal fat, especially visceral fat, appears to be a strong marker of that environment.

Some regional fat depots may be especially important. Epicardial fat — the fat surrounding the heart itself — may influence local cardiac biology more directly. Visceral abdominal fat, meanwhile, reflects a wider pattern of metabolic dysfunction that can affect blood pressure, glucose regulation, vascular health and inflammatory signalling.

That combination helps explain why abdominal obesity may outperform BMI in many risk contexts. It is not just a matter of body shape. It is a clue to the biological terrain in which heart failure develops.

Why this matters for heart failure specifically

Heart failure is not one disease with one cause. It is a syndrome with multiple pathways leading to impaired cardiac function. In some forms, especially heart failure with preserved ejection fraction, obesity, inflammation, vascular dysfunction and reduced physical capacity are increasingly recognised as major contributors.

The review on regional adiposity fits directly into that understanding. It suggests that central fat stores are tied not only to broader metabolic dysfunction but also to adverse changes in how the heart moves and responds under strain.

That is a more nuanced view of cardiovascular risk than the old framework of “more weight equals more pressure on the heart”. It suggests that where fat is located and how it behaves may be more revealing than total mass alone.

What this means in practice

For patients and clinicians, the practical implication is not that BMI should be abandoned, but that it should no longer stand alone.

Measures such as waist circumference and waist-to-hip ratio may offer useful extra information in routine care. In some cases, imaging measures of visceral fat or epicardial fat may provide even richer insight, although these are not practical as population-wide tools.

The more immediate lesson is that cardiometabolic risk assessment needs to move beyond weight categories alone. A person with a “non-alarming” BMI may still carry significant abdominal adiposity and substantial risk. Equally, weight alone may sometimes overstate or misrepresent danger if fat distribution is not considered.

That matters in a UK context, where obesity, diabetes, cardiovascular disease and heart failure all place substantial pressure on health services. Better targeting of risk could help identify people who might otherwise be missed if attention stays fixed on BMI.

A note of caution

The overall direction of the evidence is clear, but the headline still simplifies a more complex picture.

Not all of the studies supplied directly compare abdominal fat and BMI in the same prospective way. Much of the evidence is review-based rather than centred on one definitive trial. And different ways of measuring abdominal adiposity — waist circumference, waist-to-hip ratio, imaging-defined visceral fat, epicardial fat — are not identical.

So the most careful conclusion is not that belly fat is always and universally a better predictor than BMI in every situation. It is that regional adiposity measures often appear more informative than BMI alone in important cardiovascular and inflammatory contexts.

That is still a meaningful shift.

What this means for prevention

If abdominal fat truly reflects a more harmful metabolic pattern, then prevention efforts need to focus less on weight in the abstract and more on reducing the specific kinds of fat that carry the greatest biological cost.

That does not change the broad lifestyle advice: regular physical activity, improved diet quality, better sleep, and attention to insulin resistance still matter. But it does change how success might be understood.

The aim is not merely a lower number on the scales. It is a lower-risk biological profile.

That may help move the conversation about weight and heart health in a more clinically useful direction — away from simplistic categories and towards a better understanding of what the body is actually doing.

The bottom line

The strongest message from this research is not simply that obesity matters for heart failure. It is that fat distribution may matter more than total body weight alone.

BMI remains a useful starting point, but it cannot tell us where fat is stored or how biologically harmful that fat may be. Abdominal and visceral fat appear to offer more meaningful clues about inflammation, metabolic strain and heart failure risk.

Put simply, the heart may be paying closer attention to the waistline than the BMI chart can reveal.